News
Is AI the answer to our greatest global health challenge?

AI is increasingly used in healthcare to diagnose and treat patients effectively.
In terms of ageing population challenges, AI can help to ease the burden on healthcare settings as well as picking up any early warning signs.
The latest innovations include those that aid diagnosis and prognosis, and enable older people to live longer, more independent lives.
AT World reports on some of the biggest advances in age-focused AI.
Hearing aids – and more
Generally from the age of 70, hearing can start to deteriorate and, while hearing aids are nothing new, AI is being used to make them more effective than ever.
For example, US company Starkey is using AI, sensors and digital technology to track hearing aid users’ fitness, detect falls and even translate languages.
The latter is achieved through the Starkey app which connects to Google Translate; when the hearing aid detects a foreign language, it can then be translated into English via the connected smartphone and streamed back into the hearing aid and transcribed on-screen.
The product also features sensors, such as accelerometers and gyroscopes that can add additional features and tools, tracking users’ health or understanding if the user has fallen alerting a carer or family member.
Cancer treatment
While cancer can affect anyone at any age, its prevalence rises with age – while the effectiveness of treatment lowers.
A number of AI-driven innovations have been introduced to assess how patients will respond to certain treatments, particularly chemotherapy.
In one example, researchers from Denmark created a system to detect which patients are at the highest risk of developing debilitating side effects from the treatment.
It was able to successfully identify over 90 per cent of patients who were at low risk from developing nephrotoxicity – a rapid deterioration in kidney function due to toxic effect of medications and chemicals.
Closer to home, scientists at the University of Leeds created a similar algorithm for elderly bowel cancer patients, assessing their levels of two key proteins which could then determine how a patient would respond to chemotherapy.
Diagnosing dementia
Earlier this year, a Cambridge University team, along with The Alan Turing Institute, announced the development of machine learning tools that can detect dementia in patients at a very early stage.
Using brain scans from patients who went on to develop Alzheimer’s, the algorithm learned to spot structural changes in the brain, which, when combined with results from standard memory tests, the was able to evaluate the likelihood of the individual having Alzheimer’s disease.
Remote monitoring
Loss of independence is a common struggle for the elderly; increasing care needs mean many older people feel unable to stay in their own homes as long as they would like.
AI can help to monitor patients in their own homes, while alerting clinicians to any worrying signs such as deterioration.
One such example is Imperial College Healthcare NHS Trust’s partnership with remote healthcare innovator Luscii to allow heart failure patients to self-monitor their vital signs at home
Users can carry out regular checks on their weight, blood pressure and general condition without having to attend a healthcare setting – something that often presents logistical difficulties aside from the fears surrounding Covid-19.
Powered by AI, the Luscii platform has been designed to spot early warning signs of patient deterioration, alerting medical staff who can then triage the situation and provide support or resources. Additionally, the technology can also ensure that outpatients are on the right medications.
Smart technology
The world of smart technology has so a multitude of uses in elderly healthcare, from fighting loneliness to keeping dementia patients safe.
For example, a pilot project in Sweden used a voice assistant smart speaker to drive conversations about users’ memories as a way of tackling loneliness.
Participants were asked to discuss topics including their biggest loves and travel experiences, with the speakers responding with relevant follow-up questions.
Meanwhile, technology such as SafelyYou is able to monitor physical stability and analyse movement to prevent fall risk, through the use of video monitors and artificial intelligence.
Or the Buddi system is a GPS alarm fitted to a silicone wrist strap, which also features an integrated fall detector and alarm button. The wristband sends a signal to a clip that can be attached to clothing, keys or carried in a handbag and which dials through to a 24/7 monitoring centre should a fall occur.
In the home, wearables such as CarePredict can track the activity that a person is likely to be engaged in by analysing the patterns in their gestures, among other data.
If repetitive eating motions aren’t detected as expected, a carer is alerted, or the system identifies someone as being in the bathroom and it detects a sitting posture, it can be inferred that the person “is using the toilet”, notes one of its patents.
Should a change to expected patterns be observed, such as a lack of movement or wandering outside usual boundaries, carers or family can be alerted.
Wellness
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
News
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








